{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:08:27Z","timestamp":1763132907471,"version":"3.45.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI1400136"],"award-info":[{"award-number":["ICI1400136"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03350-0","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:40:54Z","timestamp":1759754454000},"page":"6030-6044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Functional Genetic Score in the ZMIZ1\/TGF-\u03b2\/STAT Pathway Predicts Early Biologic Discontinuation in Psoriasis Patients Treated with Anti-TNF and Anti-IL12\/23 Agents"],"prefix":"10.1007","volume":"42","author":[{"given":"Juan","family":"de Luque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Moch\u00f3n-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Rivera-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Gay-Mimbrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judilyn","family":"Fuentes-Duculan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Coats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Aguilar-Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Isla-Tejera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio V\u00e9lez-Garc\u00eda","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gal\u00e1n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa L\u00f3pez-Vi\u00f1au","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"Suarez-Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-4107","authenticated-orcid":false,"given":"Juan","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"6","key":"3350_CR1","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320. https:\/\/doi.org\/10.1080\/09546634.2022.2081655.","journal-title":"J Dermatolog Treat"},{"key":"3350_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251327926","author":"L Barenbrug","year":"2025","unstructured":"Barenbrug L, van der Molen RG, Maurits JSF, Seyger MMB, Otero ME, Gostynski AH, et al. Lower drug survival, less satisfaction and more adverse events in females using biologics for psoriasis: results of the Dutch BioCAPTURE registry. J Psoriasis Psoriatic Arthritis. 2025. https:\/\/doi.org\/10.1177\/24755303251327926.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"issue":"3","key":"3350_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450\u20138. https:\/\/doi.org\/10.1111\/bjd.17738.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3350_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.14552","volume":"175","author":"J Zweegers","year":"2016","unstructured":"Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340\u20137. https:\/\/doi.org\/10.1111\/bjd.14552.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3350_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/bjd\/ljaf017","volume":"192","author":"OA Alabas","year":"2025","unstructured":"Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Griffiths CEM, et al. Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2025;192(5):907\u201316. https:\/\/doi.org\/10.1093\/bjd\/ljaf017.","journal-title":"Br J Dermatol"},{"key":"3350_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf224","author":"OA Alabas","year":"2025","unstructured":"Alabas OA, Evans I, Mcelhone K, Yiu ZZN, Reynolds NJ, Laws PM, et al. Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort. Clin Exp Dermatol. 2025. https:\/\/doi.org\/10.1093\/ced\/llaf224.","journal-title":"Clin Exp Dermatol."},{"key":"3350_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20739","author":"L Motedayen Aval","year":"2025","unstructured":"Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20739.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"3350_CR8","doi-asserted-by":"publisher","first-page":"15382","DOI":"10.1038\/ncomms15382","volume":"8","author":"LC Tsoi","year":"2017","unstructured":"Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382. https:\/\/doi.org\/10.1038\/ncomms15382.","journal-title":"Nat Commun"},{"issue":"12","key":"3350_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/blood-2018-02-835850","volume":"132","author":"Q Wang","year":"2018","unstructured":"Wang Q, Yan R, Pinnell N, McCarter AC, Oh Y, Liu Y, et al. Stage-specific roles for Zmiz1 in notch-dependent steps of early T-cell development. Blood. 2018;132(12):1279\u201392. https:\/\/doi.org\/10.1182\/blood-2018-02-835850.","journal-title":"Blood"},{"issue":"3","key":"3350_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007260","volume":"4","author":"A Goris","year":"2012","unstructured":"Goris A, Liston A. The immunogenetic architecture of autoimmune disease. Cold Spring Harb Perspect Biol. 2012;4(3):a007260. https:\/\/doi.org\/10.1101\/cshperspect.a007260.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"3350_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1086\/302932","volume":"66","author":"RP Nair","year":"2000","unstructured":"Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet. 2000;66(6):1833\u201344. https:\/\/doi.org\/10.1086\/302932.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"3350_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ajhg.2021.03.009","volume":"108","author":"M Caliskan","year":"2021","unstructured":"Caliskan M, Brown CD, Maranville JC. A catalog of GWAS fine-mapping efforts in autoimmune disease. Am J Hum Genet. 2021;108(4):549\u201363. https:\/\/doi.org\/10.1016\/j.ajhg.2021.03.009.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3350_CR13","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1038\/s41467-022-34323-4","volume":"13","author":"MT Patrick","year":"2022","unstructured":"Patrick MT, Li Q, Wasikowski R, Mehta N, Gudjonsson JE, Elder JT, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1):6565. https:\/\/doi.org\/10.1038\/s41467-022-34323-4.","journal-title":"Nat Commun"},{"issue":"5","key":"3350_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/bjd\/ljad481","volume":"190","author":"OA Alabas","year":"2024","unstructured":"Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Dand N, Barker JN, et al. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2024;190(5):689\u2013700. https:\/\/doi.org\/10.1093\/bjd\/ljad481.","journal-title":"Br J Dermatol"},{"issue":"11","key":"3350_CR15","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/jdv.20143","volume":"38","author":"A Chiricozzi","year":"2024","unstructured":"Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa JM, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024;38(11):2175\u201385. https:\/\/doi.org\/10.1111\/jdv.20143.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3350_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14712598.2023.2194485","volume":"23","author":"M Galluzzo","year":"2023","unstructured":"Galluzzo M, Marcelli L, Vellucci L, Paganini C, Maffei V, Tofani L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23(4):371\u201381. https:\/\/doi.org\/10.1080\/14712598.2023.2194485.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3350_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","volume":"12","author":"CM Lewis","year":"2020","unstructured":"Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44. https:\/\/doi.org\/10.1186\/s13073-020-00742-5.","journal-title":"Genome Med"},{"issue":"1","key":"3350_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41598-023-27637-w","volume":"13","author":"S van Dam","year":"2023","unstructured":"van Dam S, Folkertsma P, Castela Forte J, de Vries DH, Herrera Cunillera C, Gannamani R, et al. The necessity of incorporating non-genetic risk factors into polygenic risk score models. Sci Rep. 2023;13(1):1351. https:\/\/doi.org\/10.1038\/s41598-023-27637-w.","journal-title":"Sci Rep"},{"issue":"1","key":"3350_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biomedicines13010005","volume":"13","author":"A Rodr\u00edguez-Lopez","year":"2024","unstructured":"Rodr\u00edguez-Lopez A, Mart\u00ednez-Sendino M, Prieto-P\u00e9rez R, Soria-Chacartegui P, Gonz\u00e1lez-Iglesias E, Aparicio-Dom\u00ednguez M, et al. Ten-year persistence of biologic drugs in psoriasis and its relationship with pharmacogenetic biomarkers. Biomedicines. 2024;13(1):5. https:\/\/doi.org\/10.3390\/biomedicines13010005.","journal-title":"Biomedicines"},{"issue":"6","key":"3350_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","volume":"155","author":"LJ van Vugt","year":"2019","unstructured":"van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(6):708\u201315. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0098.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3350_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","volume":"19","author":"MC Ovejero-Benito","year":"2018","unstructured":"Ovejero-Benito MC, Mu\u00f1oz-Aceituno E, Reolid A, Saiz-Rodr\u00edguez M, Abad-Santos F, Daud\u00e9n E. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19(2):209\u201322. https:\/\/doi.org\/10.1007\/s40257-017-0322-9.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"3350_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040293","volume":"11","author":"C Membrive Jim\u00e9nez","year":"2021","unstructured":"Membrive Jim\u00e9nez C, P\u00e9rez Ram\u00edrez C, S\u00e1nchez Mart\u00edn A, Vieira Maroun S, Arias Santiago SA, Ram\u00edrez Tortosa MDC, et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe psoriasis. J Pers Med. 2021;11(4):293. https:\/\/doi.org\/10.3390\/jpm11040293.","journal-title":"J Pers Med"},{"issue":"9","key":"3350_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091394","volume":"12","author":"A Siemens","year":"2022","unstructured":"Siemens A, Anderson SJ, Rassekh SR, Ross CJD, Carleton BC. A systematic review of polygenic models for predicting drug outcomes. J Pers Med. 2022;12(9):1394. https:\/\/doi.org\/10.3390\/jpm12091394.","journal-title":"J Pers Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03350-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03350-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03350-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:17Z","timestamp":1763132657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03350-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3350"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03350-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"James Krueger has served as a consultant or received honoraria from AbbVie, Aclaris Therapeutics, Allergan, Almirall, Amgen, Arena Pharmaceuticals, Aristea Therapeutics, Asana BioSciences, Aurigene, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Escalier Biosciences, Galapagos, Janssen, Lilly, MoonLake Immunotherapeutics, Nimbus Therapeutics, Novartis, Pfizer, Sanofi, Sienna Biopharmaceuticals, Sun Pharma, Target-Derm, UCB, Valeant, and Ventyx. Juan Ruano has received research funding from Pfizer Inc. and has served as a scientific advisor and\/or clinical investigator in studies sponsored by Pfizer Inc., AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte, Janssen, Kymab, LEO Pharma, Novartis, Regeneron, Sandoz, Sanofi Genzyme, and UCB Pharma. The remaining authors; Juan de Luque, Carmen Moch\u00f3n-Jim\u00e9nez, Irene Rivera-Ruiz, Jes\u00fas Gay-Mimbrera, Judilyn Fuentes-Duculan, Israel Coats, Macarena Aguilar-Luque, Beatriz Isla-Tejera, Antonio V\u00e9lez-Garc\u00eda Nieto, Manuel Gal\u00e1n-Guti\u00e9rrez, Teresa L\u00f3pez-Vi\u00f1au L\u00f3pez and Mayte Suarez-Fari\u00f1as declare no conflicts of interest relevant to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted using data from a previously established cohort of patients with moderate-to-severe psoriasis, collected as part of routine clinical care. All participants provided written informed consent. The study complied with the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of C\u00f3rdoba (Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n de C\u00f3rdoba, CEI)\u2014Registration ICI1400136-1\u2013. The study is registered on ClinicalTrials.gov under the identifier NCT07041112.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}